SEC Company Response from Repare Therapeutics Inc. (RPTX) (CIK 0001808158) — Jun 16, 2020
Repare Therapeutics Inc. (RPTX) (CIK 0001808158)
Date: June 16, 2020 · CIK: 0001808158 · Accession: 0001193125-20-170409
AI Filing Summary & Sentiment
File numbers found in text: 333-238822
Letter
June 16, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Tracey McKoy
Ms. Kate Tillan
Mr. Tim Buchmiller
Ms. Celeste Murphy
Re: Repare Therapeutics Inc.
Registration Statement on Form S-1
Registration No. 333-238822
Acceleration Request
Requested Date: June 18, 2020
Requested Time: 4:00 PM, Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters, hereby join Repare Therapeutics Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-238822) (the “Registration Statement”) to become effective on June 18, 2020, at 4:00 PM, Eastern Daylight Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Very truly yours,
Morgan Stanley & Co. LLC
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
June 16, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Tracey McKoy
Ms. Kate Tillan
Mr. Tim Buchmiller
Ms. Celeste Murphy
Re:
Repare Therapeutics Inc.
Registration Statement on Form S-1
Registration No. 333-238822
Acceleration Request
Requested Date: June 18, 2020
Requested Time: 4:00 PM, Eastern Daylight Time
Ladies and Gentlemen:
In accordance with Rule
461 under the Securities Act of 1933, as amended (the “Act”), Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several
underwriters, hereby join Repare Therapeutics Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-238822) (the “Registration Statement”) to become effective on June 18, 2020, at 4:00 PM, Eastern Daylight Time, or as soon
as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate
distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule
15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Very truly yours,
Morgan Stanley & Co. LLC
By:
/s/ Kalli Dircks
Name:
Kalli Dircks
Title:
Executive Director
Goldman Sachs & Co. LLC
By:
/s/ Matthew Leskowitz
Name:
Matthew Leskowitz
Title:
Managing Director
Cowen and Company, LLC
By:
/s/ Bill Follis
Name:
Bill Follis
Title:
Managing Director
Piper Sandler & Co.
By:
/s/ Neil Riley
Name:
Neil Riley
Title:
Managing Director
cc:
Lloyd M. Segal, Repare Therapeutics Inc.
Mitchell S. Bloom, Goodwin Procter LLP
Seo Salimi, Goodwin Procter LLP
Divakar Gupta, Cooley LLP
Ryan S. Sansom, Cooley LLP
Marc A. Recht, Cooley LLP
Courtney T. Thorne, Cooley LLP
[Signature Page to Acceleration Request]